Details of the Drug

General Information of Drug (ID: DML6CN4)

Drug Name
Acemetacin
Synonyms
Acemetacina; Acemetacina [INN-Spanish]; Acemetacine; Acemetacine [INN-French]; Acemetacinum; Acemetacinum [INN-Latin]; Acemix; Aximeixin; Emflex; Rantudil; Rheumibis; TVX 3322; indometacin carboxymethyl ester; indometacin glycolic ester; indomethacin carboxymethyl ester; indomethacin glycolic ester; 1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-, carboxymethyl ester; 53164-05-9; BRN 0501672; Bay f 4975; C21H18ClNO6; CHEBI:31162; CHEMBL189171; EINECS 258-403-4; K 708; K-708; UNII-5V141XK28X; acemetacin
Affected Organisms
Humans and other mammals
ATC Code
M01AB11: Acemetacin
M01AB: Acetic acid derivatives and related substances
M01A: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
M01: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
M: MUSCULO-SKELETAL SYSTEM
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 415.8
Logarithm of the Partition Coefficient (xlogp) 4.2
Rotatable Bond Count (rotbonds) 7
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 6
ADMET Property
Absorption AUC
The area under the plot of plasma concentration (AUC) of drug is 483-712 mcgh/L [1]
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 276.8 mcg/L [1]
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 2.5 h [1]
Clearance
The clearance of drug is 4.59 mL/min/kg [2]
Elimination
The elimination of acemetacin is divided in renal elimination that covers 40% of the complete administered dose and the restant 60% is excreted in feces []
Half-life
The concentration or amount of drug in body reduced by one-half in 4.5 hours [3]
Metabolism
The drug is metabolized via the esterolytic cleavage to form its major and active metabolite indometacin []
Vd
The volume of distribution (Vd) of drug is 0.5-0.7 L/kg []
Chemical Identifiers
Formula
C21H18ClNO6
IUPAC Name
2-[2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetyl]oxyacetic acid
Canonical SMILES
CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)OCC(=O)O
InChI
InChI=1S/C21H18ClNO6/c1-12-16(10-20(26)29-11-19(24)25)17-9-15(28-2)7-8-18(17)23(12)21(27)13-3-5-14(22)6-4-13/h3-9H,10-11H2,1-2H3,(H,24,25)
InChIKey
FSQKKOOTNAMONP-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
1981
ChEBI ID
CHEMBL189171
CAS Number
53164-05-9
UNII
5V141XK28X
DrugBank ID
DB13783
INTEDE ID
DR0035
Drug-Molecule Activity Atlas (DMA)NEW Click to Jump to the Detailed DMA Information of This Drug
Drug Pharmacogenomic Perturbation (DPP)NEW Click to Jump to the Detailed DPP Information of This Drug
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
UDP-glucuronosyltransferase 2B7 (UGT2B7)
Main DME 		DEB3CV1 UD2B7_HUMAN Substrate [4]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Jones RW, Collins AJ, Notarianni LJ, Sedman E: The comparative pharmacokinetics of acemetacin in young subjects and elderly patients. Br J Clin Pharmacol. 1991 May;31(5):543-5.
2 Ochs HR, Schuppan U, Greenblatt DJ, Abernethy DR: Reduced distribution and clearance of acetaminophen in patients with congestive heart failure. J Cardiovasc Pharmacol. 1983 Jul-Aug;5(4):697-9.
3 [Metabolism and pharmacokinetics of acemetacin in man (author's transl)]. Arzneimittelforschung. 1980;30(8A):1391-8.
4 Seyffart G. (1992). Drug dosage in renal insufficiency (2nd ed.). Springer Science+Business Media Dordrecht.